IKT - Inhibikase Therapeutics Inc

IKT - Inhibikase Therapeutics Inc

https://www.inhibikase.com

Strong Sell Momentum: Bearish

Recent News

Powered by Alpha Vantage

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - Inhibikase Therapeutics ( NASDAQ:IKT )

Benzinga • 3 weeks, 6 days ago • score: 0.16

BOSTON and ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc.

Inhibikase Posts Wider Loss in Q2

Motley Fool • 1 month ago • score: 0.21

Inhibikase Therapeutics ( NASDAQ:IKT ) released its earnings for the quarter ended June 30, 2025 on August 14, 2025. The company reported a GAAP net loss per share of $0.11, wider than the analyst expectation of a GAAP loss of $0.08 per share. There was no revenue as the company remains ...

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

GlobeNewswire • 1 month ago • score: 0.13

BOSTON and ATLANTA, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc. ( Nasdaq: IKT ) ( "Inhibikase" or "Company" ) , a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ( "PAH" ) ...

Inhibikase Therapeutics ( IKT ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Commentary • 6 months, 1 week ago • score: 0.44

Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Cytokinetics ( NASDAQ:CYTK )

Benzinga • 10 months, 1 week ago • score: 0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.

52W High

$4.20

52W Low

$1.12

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.92

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.34

EV/Revenue (<3 favorable)

2.75

P/S (TTM) (<3 favorable)

1000000.00

P/B (<3 favorable)

1.55

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

12.99%

Institutions (25–75% balanced)

78.04%

Shares Outstanding

74,517,000

Float

24,966,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1

Gross Profit (TTM)

-27,167,984

EPS (TTM)

-0.04

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.98%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

-0.0435

Previous

-0.0327

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025